Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/53066
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim W.S. | - |
dc.contributor.author | Shortt J. | - |
dc.contributor.author | Zinzani P.L. | - |
dc.contributor.author | Mikhailova N. | - |
dc.contributor.author | Radeski D. | - |
dc.contributor.author | Ribrag V. | - |
dc.contributor.author | Domenech E.D. | - |
dc.contributor.author | Sawas A. | - |
dc.contributor.author | Alexis K. | - |
dc.contributor.author | Emig M. | - |
dc.contributor.author | Elbadri R. | - |
dc.contributor.author | Hajela P. | - |
dc.contributor.author | Ravenstijn P. | - |
dc.contributor.author | Pinto S. | - |
dc.contributor.author | Garcia L. | - |
dc.contributor.author | Overesch A. | - |
dc.contributor.author | Pietzko K. | - |
dc.contributor.author | Horwitz S. | - |
dc.date.accessioned | 2025-01-20T00:24:52Z | - |
dc.date.available | 2025-01-20T00:24:52Z | - |
dc.date.copyright | 2025 | - |
dc.date.issued | 2025-01-14 | en |
dc.identifier.citation | Clinical Cancer Research. 31(1) (pp 65-73), 2025. Date of Publication: 01 Jan 2025. | - |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/53066 | - |
dc.description.abstract | Purpose: Patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) generally have poor prognoses and limited treatment options. This study evaluated the efficacy of a novel CD30/CD16A bispecific innate cell engager, acimtamig (AFM13), in patients with R/R PTCL. Patients and Methods: Patients included those with CD30 expression in >=1% of tumor cells and who were R/R following >=1 prior line of systemic therapy. Acimtamig (200 mg) was administered once weekly in 8-week cycles. The primary endpoint was the overall response rate by fluorodeoxyglucose-PET per independent review committee; secondary and exploratory endpoints included duration of response, safety, progression-free survival, and overall survival. Result(s): The overall response rate in 108 patients was 32.4% [95% confidence interval (CI), 23.7, 42.1] with a complete response rate of 10.2% (95% CI, 5.2, 17.5); the median duration of response was 2.3 months (95% CI, 1.9, 6.5). Patients with R/R angioimmunoblastic T-cell lymphoma exhibited the greatest number of responses [53.3% (95% CI, 34.3, 71.7)]. Responses were independent of CD30 expression level, prior brentuximab vedotin treatment, or steroid premedication. Acimtamig exhibited a tolerable safety profile; the most common treatment-related adverse events were infusion-related reactions in 27 patients (25.0%) and neutropenia in 11 patients (10.2%). No cases of cytokine release syndrome or acimtamig-related deaths were reported. Despite exhibiting promising clinical activity and tolerable safety in a heavily pretreated PTCL population, the study did not meet the criteria for the primary endpoint. Conclusion(s): The promising clinical efficacy observed warrants further investigation, and development of acimtamig for patients with R/R CD30+ lymphomas continues in combination with allogeneic NK cells.Copyright ©2024 The Authors. | - |
dc.publisher | American Association for Cancer Research Inc. | - |
dc.relation.ispartof | Clinical Cancer Research | - |
dc.subject.mesh | angioimmunoblastic T cell lymphoma | - |
dc.subject.mesh | cytokine release syndrome | - |
dc.subject.mesh | infusion related reaction | - |
dc.subject.mesh | neutropenia | - |
dc.subject.mesh | peripheral T cell lymphoma | - |
dc.subject.mesh | systemic therapy | - |
dc.title | A phase II study of acimtamig (AFM13) in patients with CD30-positive, relapsed, or refractory peripheral T-cell lymphomas. | - |
dc.type | Article | - |
dc.identifier.affiliation | Haematology | - |
dc.type.studyortrial | Clinical trial | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1158/1078-0432.CCR-24-1913 | - |
dc.publisher.place | United States | - |
dc.identifier.pubmedid | 39531538 | - |
dc.identifier.institution | (Kim) Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea | - |
dc.identifier.institution | (Shortt) Department of Medicine, School of Clinical Sciences, Faculty of Medicine, Nursing & Health Sciences, Monash University, Clayton, VIC, Australia | - |
dc.identifier.institution | (Shortt) Monash Hematology, Monash Health, Clayton, VIC, Australia | - |
dc.identifier.institution | (Zinzani) IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia "Seragnoli,", Bologna, Italy | - |
dc.identifier.institution | (Zinzani) Dipartimento di Scienze Mediche e Chirurgiche, Universita di Bologna, Bologna, Italy | - |
dc.identifier.institution | (Mikhailova) Raisa Gorbacheva Memorial Institute of Children Oncology Hematology and Transplantation, First Saint Petersburg State Pavlov Medical University, Saint Petersburg, Russian Federation | - |
dc.identifier.institution | (Radeski) Linear Clinical Research & Sir Charles Gairdner Hospital, Perth, WA, Australia | - |
dc.identifier.institution | (Ribrag) Institut Gustave Roussy, Villejuif, France | - |
dc.identifier.institution | (Domenech) Institut Catala d'Oncologia, Hospital Duran i Reynals, IDIBELL, Barcelona, Spain | - |
dc.identifier.institution | (Sawas) Columbia University Medical Center, New York, NY, United States | - |
dc.identifier.institution | (Alexis, Garcia) Affimed Inc., New York, NY, United States | - |
dc.identifier.institution | (Emig, Elbadri, Hajela, Ravenstijn, Pinto, Overesch, Pietzko) Affimed GmbH, Mannheim, Germany | - |
dc.identifier.institution | (Horwitz) Memorial Sloan Kettering Cancer Center, New York, NY, United States | - |
dc.identifier.affiliationmh | (Shortt) Monash Hematology, Monash Health, Clayton, VIC, Australia | - |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.openairetype | Article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
crisitem.author.dept | Haematology | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.